[{"id":"cc900cf1-cbd5-4b72-929f-5a7f0c8da6dd","acronym":"KEYNOTE-797","url":"https://clinicaltrials.gov/study/NCT04042701","created_at":"2021-01-18T19:49:50.989Z","updated_at":"2025-02-25T12:37:23.766Z","phase":"Phase 1","brief_title":"DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04042701 - KEYNOTE-797","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • HER-2 • BRAF • ALK • ROS1","pipe":" | ","alterations":" HER-2 positive • BRAF V600E • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ALK mutation • ROS1 fusion","tags":["EGFR • HER-2 • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRAF V600E • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ALK mutation • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 02/10/2020","start_date":" 02/10/2020","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2025-02-24"},{"id":"be73eee7-8633-483e-a581-812fd81e01b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04929041","created_at":"2021-06-18T23:52:29.992Z","updated_at":"2025-02-25T14:02:22.824Z","phase":"Phase 2/3","brief_title":"Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative","source_id_and_acronym":"NCT04929041","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • ALK mutation","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed • ABP 206 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 427","initiation":"Initiation: 10/07/2022","start_date":" 10/07/2022","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-19"},{"id":"c55cbb14-94c1-43f6-a3b4-860f9b9fda2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04716946","created_at":"2021-01-24T15:53:01.720Z","updated_at":"2025-02-25T14:59:39.962Z","phase":"Phase 2","brief_title":"Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy","source_id_and_acronym":"NCT04716946","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR • ALK • CTLA4","pipe":" | ","alterations":" EGFR mutation • ALK mutation","tags":["EGFR • ALK • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 01/27/2021","start_date":" 01/27/2021","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2025-02-13"},{"id":"393ae514-083b-4a6f-a6c0-c472fe56deef","acronym":"KEYNOTE-E59","url":"https://clinicaltrials.gov/study/NCT05083481","created_at":"2021-10-19T15:58:03.788Z","updated_at":"2025-02-25T15:19:18.701Z","phase":"Phase 1/2","brief_title":"A Study of ASP1570 Alone or in Combination With Pembrolizumab or Standard Therapies in Adults With Solid Tumors","source_id_and_acronym":"NCT05083481 - KEYNOTE-E59","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" EGFR • NTRK","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • ALK positive • ALK mutation • NTRK fusion","tags":["EGFR • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • ALK positive • ALK mutation • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • docetaxel • Lonsurf (trifluridine/tipiracil) • ASP1570"],"overall_status":"Recruiting","enrollment":" Enrollment 310","initiation":"Initiation: 10/19/2021","start_date":" 10/19/2021","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-02-12"},{"id":"6eaf7ebc-3a8d-431d-b6e5-611012b34a31","acronym":"KEYNOTE B81","url":"https://clinicaltrials.gov/study/NCT04609566","created_at":"2021-01-19T20:32:09.814Z","updated_at":"2025-02-25T16:10:46.045Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors","source_id_and_acronym":"NCT04609566 - KEYNOTE B81","lead_sponsor":"Seagen Inc.","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • ALK mutation","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Adcetris (brentuximab vedotin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 142","initiation":"Initiation: 01/26/2021","start_date":" 01/26/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-07"},{"id":"6da256ca-a5e6-48f5-9386-baa4180b20fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT03420508","created_at":"2021-01-18T16:52:29.427Z","updated_at":"2025-02-25T16:52:07.457Z","phase":"Phase 2","brief_title":"Treating Patients With Melanoma and ALK Alterations With Ensartinib","source_id_and_acronym":"NCT03420508","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF • ALK","pipe":" | ","alterations":" BRAF V600 • ALK fusion • ALK mutation","tags":["BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • ALK fusion • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ensacove (ensartinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/10/2018","start_date":" 01/10/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-04"},{"id":"24c0fcb4-b357-4530-a6a0-668b57518e71","acronym":"ARC-27","url":"https://clinicaltrials.gov/study/NCT06120075","created_at":"2023-11-07T16:14:23.781Z","updated_at":"2025-02-25T17:32:32.864Z","phase":"Phase 1","brief_title":"A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies","source_id_and_acronym":"NCT06120075 - ARC-27","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" EGFR • PD-L1 • ALK • MET • RET • ROS1 • STK11 • NTRK","pipe":" | ","alterations":" EGFR mutation • STK11 mutation • ALK mutation","tags":["EGFR • PD-L1 • ALK • MET • RET • ROS1 • STK11 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • STK11 mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Yutuo (zimberelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 91","initiation":"Initiation: 01/19/2024","start_date":" 01/19/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2025-01-30"},{"id":"f118d9dd-fc64-4af9-8bab-857966be64c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05858164","created_at":"2023-05-15T14:04:14.690Z","updated_at":"2025-02-25T17:12:30.889Z","phase":"Phase 1","brief_title":"A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05858164","lead_sponsor":"Bayer","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK mutation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAY 2862789"],"overall_status":"Recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 08/07/2023","start_date":" 08/07/2023","primary_txt":" Primary completion: 03/02/2027","primary_completion_date":" 03/02/2027","study_txt":" Completion: 03/02/2027","study_completion_date":" 03/02/2027","last_update_posted":"2025-01-22"},{"id":"a7d87c22-61ed-4880-930a-7f94876963f9","acronym":"KEYNOTE-E64","url":"https://clinicaltrials.gov/study/NCT04787042","created_at":"2021-03-08T12:53:50.679Z","updated_at":"2025-02-25T16:11:14.799Z","phase":"Phase 1/2","brief_title":"Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067","source_id_and_acronym":"NCT04787042 - KEYNOTE-E64","lead_sponsor":"Simcha IL-18, Inc.","biomarkers":" ALK • TMB • MSI","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR • ALK positive • ALK mutation","tags":["ALK • TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR • ALK positive • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Gazyva (obinutuzumab) • vevoctadekin (ST-067)"],"overall_status":"Recruiting","enrollment":" Enrollment 316","initiation":"Initiation: 08/06/2021","start_date":" 08/06/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-11-15"},{"id":"50e95443-c92c-48dc-b638-e94294dd906a","acronym":"KEYNOTE-A72","url":"https://clinicaltrials.gov/study/NCT03260322","created_at":"2021-01-18T16:06:27.240Z","updated_at":"2025-02-25T16:06:46.737Z","phase":"Phase 1","brief_title":"A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT03260322 - KEYNOTE-A72","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ASP8374"],"overall_status":"Completed","enrollment":" Enrollment 169","initiation":"Initiation: 09/08/2017","start_date":" 09/08/2017","primary_txt":" Primary completion: 05/10/2022","primary_completion_date":" 05/10/2022","study_txt":" Completion: 05/10/2022","study_completion_date":" 05/10/2022","last_update_posted":"2024-11-13"},{"id":"cc0e252d-323c-463e-9f6b-bb8fa47915a5","acronym":"KEYNOTE-A87","url":"https://clinicaltrials.gov/study/NCT03565445","created_at":"2021-01-18T17:32:45.491Z","updated_at":"2025-02-25T16:08:02.730Z","phase":"Phase 1","brief_title":"A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT03565445 - KEYNOTE-A87","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • ASP1948"],"overall_status":"Completed","enrollment":" Enrollment 190","initiation":"Initiation: 07/02/2018","start_date":" 07/02/2018","primary_txt":" Primary completion: 03/27/2023","primary_completion_date":" 03/27/2023","study_txt":" Completion: 03/27/2023","study_completion_date":" 03/27/2023","last_update_posted":"2024-11-01"},{"id":"7c4c2c5c-0d9e-41b0-96b2-8600aa7be62a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04318938","created_at":"2021-01-18T20:55:43.511Z","updated_at":"2025-02-25T14:51:44.818Z","phase":"Phase 2","brief_title":"Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping","source_id_and_acronym":"NCT04318938","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" ALK • TP53","pipe":" | ","alterations":" TP53 mutation • ALK positive • ALK rearrangement • ALK fusion • ALK mutation","tags":["ALK • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ALK positive • ALK rearrangement • ALK fusion • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alunbrig (brigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 03/30/2020","start_date":" 03/30/2020","primary_txt":" Primary completion: 01/16/2026","primary_completion_date":" 01/16/2026","study_txt":" Completion: 01/16/2026","study_completion_date":" 01/16/2026","last_update_posted":"2024-10-14"},{"id":"2386852e-1c2a-4d97-ae6c-dd2f1c49a6e0","acronym":"NCI-2015-01097","url":"https://clinicaltrials.gov/study/NCT02498613","created_at":"2021-01-18T12:02:57.557Z","updated_at":"2025-02-25T15:06:40.982Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors","source_id_and_acronym":"NCT02498613 - NCI-2015-01097","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 expression • ALK mutation","tags":["EGFR • HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Recentin (cediranib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 122","initiation":"Initiation: 08/31/2016","start_date":" 08/31/2016","primary_txt":" Primary completion: 06/22/2022","primary_completion_date":" 06/22/2022","study_txt":" Completion: 04/10/2025","study_completion_date":" 04/10/2025","last_update_posted":"2024-09-26"},{"id":"bb7dd126-5213-42ac-be7a-cb85b653508e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03003468","created_at":"2021-01-18T14:46:25.071Z","updated_at":"2025-02-25T16:05:37.605Z","phase":"Phase 1/2","brief_title":"Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017","source_id_and_acronym":"NCT03003468","lead_sponsor":"Lawrence Feldman, MD","biomarkers":" ALK","pipe":" | ","alterations":" EGFR mutation • ALK mutation","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imprime PGG (odetiglucan)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 07/11/2017","start_date":" 07/11/2017","primary_txt":" Primary completion: 11/22/2021","primary_completion_date":" 11/22/2021","study_txt":" Completion: 11/28/2022","study_completion_date":" 11/28/2022","last_update_posted":"2024-08-13"},{"id":"03fa7b60-29a0-4a44-aa05-14a8b5df45eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02091141","created_at":"2021-01-17T17:15:36.027Z","updated_at":"2025-02-25T12:26:06.921Z","phase":"Phase 2","brief_title":"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT02091141","lead_sponsor":"Genentech, Inc.","biomarkers":" EGFR • HER-2 • BRAF • ALK • TMB • PTCH1 • SMO","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • BRAF V600 • ALK rearrangement • ALK mutation • SMO mutation","tags":["EGFR • HER-2 • BRAF • ALK • TMB • PTCH1 • SMO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • BRAF V600 • ALK rearrangement • ALK mutation • SMO mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • erlotinib • Zelboraf (vemurafenib) • Alecensa (alectinib) • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Erivedge (vismodegib)"],"overall_status":"Completed","enrollment":" Enrollment 673","initiation":"Initiation: 04/14/2014","start_date":" 04/14/2014","primary_txt":" Primary completion: 05/24/2023","primary_completion_date":" 05/24/2023","study_txt":" Completion: 05/24/2023","study_completion_date":" 05/24/2023","last_update_posted":"2024-07-23"},{"id":"ba46c2a2-b8a0-4d55-8e36-8db640687fe6","acronym":"HER2","url":"https://clinicaltrials.gov/study/NCT05650879","created_at":"2022-12-14T14:58:21.956Z","updated_at":"2024-07-02T16:34:37.125Z","phase":"Phase 1","brief_title":"ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05650879 - HER2","lead_sponsor":"Enliven Therapeutics","biomarkers":" BRAF • ALK • ROS1","pipe":" | ","alterations":" HER-2 positive • BRAF V600E • HER-2 amplification • BRAF V600 • ALK mutation","tags":["BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRAF V600E • HER-2 amplification • BRAF V600 • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • ELVN-002"],"overall_status":"Recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 03/20/2023","start_date":" 03/20/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-06-07"},{"id":"59529bbb-f615-4981-937f-6ac29b7ec1c3","acronym":"PIKACHU","url":"https://clinicaltrials.gov/study/NCT04322890","created_at":"2021-01-18T20:56:40.742Z","updated_at":"2024-07-02T16:34:59.292Z","phase":"Phase 2","brief_title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","source_id_and_acronym":"NCT04322890 - PIKACHU","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • erlotinib • gefitinib • Rozlytrek (entrectinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Ameile (aumolertinib) • Orpathys (savolitinib) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 6000","initiation":"Initiation: 04/16/2020","start_date":" 04/16/2020","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2027","study_completion_date":" 12/24/2027","last_update_posted":"2024-06-04"},{"id":"6dc986d6-2bb6-4218-af26-148a2c725a0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05584267","created_at":"2022-10-18T14:57:09.716Z","updated_at":"2024-07-02T16:34:59.956Z","phase":"Phase 2","brief_title":"Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy","source_id_and_acronym":"NCT05584267","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK mutation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 12/25/2022","start_date":" 12/25/2022","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-30"},{"id":"ea2426dc-fd65-4541-b437-a3fa2dace5ba","acronym":"Promise","url":"https://clinicaltrials.gov/study/NCT06081907","created_at":"2023-10-14T01:13:10.291Z","updated_at":"2024-07-02T16:35:00.048Z","phase":"Phase 1/2","brief_title":"The Efficacy and Safety of IBI363 in Solid Tumors","source_id_and_acronym":"NCT06081907 - Promise","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR • HER-2 • PD-L1 • BRAF • ALK • RET • CD73 • NTRK","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • RET fusion • ALK fusion • ALK mutation","tags":["EGFR • HER-2 • PD-L1 • BRAF • ALK • RET • CD73 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • RET fusion • ALK fusion • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Lenvima (lenvatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 12/25/2023","start_date":" 12/25/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2024-05-30"},{"id":"84516b21-8265-457c-a480-fa67aca332aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT04837196","created_at":"2021-04-08T12:52:25.748Z","updated_at":"2024-07-02T16:35:01.857Z","phase":"Phase 1/2","brief_title":"Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen","source_id_and_acronym":"NCT04837196","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" EGFR • BRAF • ALK • WT1","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation","tags":["EGFR • BRAF • ALK • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ASP7517"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/06/2021","start_date":" 12/06/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-05-23"},{"id":"0d7726c2-14a5-444d-8b94-705fe08c0ff2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05798845","created_at":"2023-04-05T14:03:20.140Z","updated_at":"2024-07-02T16:35:03.010Z","phase":"Phase 2","brief_title":"The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer","source_id_and_acronym":"NCT05798845","lead_sponsor":"Shanghai Chest Hospital","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • ALK mutation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Loqtorzi (toripalimab-tpzi)"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 02/20/2023","start_date":" 02/20/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-05-17"},{"id":"aecf3ac5-9504-4f3a-9a5f-7cc5aaedb65d","acronym":"NCI-2019-03212","url":"https://clinicaltrials.gov/study/NCT03965689","created_at":"2021-01-18T19:30:37.082Z","updated_at":"2024-07-02T16:35:02.796Z","phase":"Phase 2","brief_title":"Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy","source_id_and_acronym":"NCT03965689 - NCI-2019-03212","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • ALK • ROS1 • B2M • RAD51 • CD4 • NQO1 • NTRK • SLC7A11 • UBE2M • ATF3 • NAE1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • ALK mutation • ROS1 positive • SLC7A11 expression","tags":["BRAF • ALK • ROS1 • B2M • RAD51 • CD4 • NQO1 • NTRK • SLC7A11 • UBE2M • ATF3 • NAE1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • ALK mutation • ROS1 positive • SLC7A11 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/16/2020","start_date":" 04/16/2020","primary_txt":" Primary completion: 09/07/2022","primary_completion_date":" 09/07/2022","study_txt":" Completion: 03/20/2025","study_completion_date":" 03/20/2025","last_update_posted":"2024-05-17"},{"id":"7231e231-b3fe-4b99-8942-f9e61c716197","acronym":"Cabatezo-1","url":"https://clinicaltrials.gov/study/NCT05859217","created_at":"2023-05-15T14:04:28.125Z","updated_at":"2024-07-02T16:35:05.269Z","phase":"Phase 2","brief_title":"A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)","source_id_and_acronym":"NCT05859217 - Cabatezo-1","lead_sponsor":"Jun Zhang, MD, PhD","biomarkers":" EGFR • PD-L1 • BRAF • ALK • CD4","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • ALK mutation","tags":["EGFR • PD-L1 • BRAF • ALK • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-05-08"},{"id":"8e698f4d-2a78-42c5-a620-76e572d7431e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03595059","created_at":"2021-01-18T17:40:37.713Z","updated_at":"2024-07-02T16:35:05.958Z","phase":"Phase 1","brief_title":"A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors","source_id_and_acronym":"NCT03595059","lead_sponsor":"AbbVie","biomarkers":" EGFR • HER-2 • BRAF • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • BRAF mutation • HER-2 negative • ALK mutation • ROS1 positive • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["EGFR • HER-2 • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • BRAF mutation • HER-2 negative • ALK mutation • ROS1 positive • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • mirzotamab clezutoclax (ABBV-155)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 169","initiation":"Initiation: 07/13/2018","start_date":" 07/13/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-03"}]